In preclinical models, Alpelisib exhibited robust inhibitory efficacy against cancer cell lines characterized by PIK3CA mutations, alongside its capacity to diminish tumor progression within xenograft models harboring PIK3CA mutations [121]. The gene discussed is PIK3CA; the disease is cancer.